Essential Pharma

News

Carlyle backs Essential refinancing and other funding news

Essential Pharma announces a €900m recapitalisation deal, while Noema Pharma, Angitia Biopharma, Citryll, and Veradermics also raise new cash.

News

Essential adds neuroblastoma drug with Renaissance buy

Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom

News

Lundbeck preps for key bexicaserin data around year-end

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks